![Richard Porter](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard Porter
Directeur Technique/Scientifique/R&D chez UNIQURE N.V.
Fortune : 164 419 $ au 31/05/2024
Postes actifs de Richard Porter
Sociétés | Poste | Début | Fin |
---|---|---|---|
UNIQURE N.V. | Directeur Technique/Scientifique/R&D | 05/10/2023 | - |
Corporate Officer/Principal | 01/04/2022 | 05/10/2023 |
Historique de carrière de Richard Porter
Anciens postes connus de Richard Porter
Sociétés | Poste | Début | Fin |
---|---|---|---|
Therachon AG | Directeur des opérations | 01/07/2016 | 01/07/2019 |
Roche Group
![]() Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Directeur Technique/Scientifique/R&D | 01/03/2014 | 01/08/2016 |
Shire Plc /Old/
![]() Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01/09/2011 | 01/02/2014 |
Corlieve Therapeutics SAS
![]() Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Directeur/Membre du Conseil | 01/11/2019 | - |
Directeur Général | 01/11/2019 | - | |
Fondateur | 01/11/2019 | - |
Formation de Richard Porter
The University of Southampton | Doctorate Degree |
Statistiques
Internationale
Royaume-Uni | 3 |
Suisse | 3 |
France | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
UNIQURE N.V. | Health Technology |
Entreprise privées | 4 |
---|---|
Corlieve Therapeutics SAS
![]() Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Health Technology |
Therachon AG | |
Roche Group
![]() Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Shire Plc /Old/
![]() Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
- Bourse
- Insiders
- Richard Porter
- Expérience